These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 22169894)

  • 1. A monoclonal antibody to the human HER3 receptor inhibits Neuregulin 1-beta binding and co-operates with Herceptin in inhibiting the growth of breast cancer derived cell lines.
    Blackburn E; Zona S; Murphy ML; Brown IR; Chan SK; Gullick WJ
    Breast Cancer Res Treat; 2012 Jul; 134(1):53-9. PubMed ID: 22169894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of inhibition effect of herceptin on interaction between heregulin and erbB receptors HER3/HER2 by single-molecule force spectroscopy.
    Shi X; Xu L; Yu J; Fang X
    Exp Cell Res; 2009 Oct; 315(16):2847-55. PubMed ID: 19497323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
    Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
    Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.
    Yakes FM; Chinratanalab W; Ritter CA; King W; Seelig S; Arteaga CL
    Cancer Res; 2002 Jul; 62(14):4132-41. PubMed ID: 12124352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Additive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast cancer cells.
    Scotti ML; Langenheim JF; Tomblyn S; Springs AE; Chen WY
    Breast Cancer Res Treat; 2008 Sep; 111(2):241-50. PubMed ID: 17955362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo.
    Jerome L; Alami N; Belanger S; Page V; Yu Q; Paterson J; Shiry L; Pegram M; Leyland-Jones B
    Cancer Res; 2006 Jul; 66(14):7245-52. PubMed ID: 16849573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small-animal SPECT/CT of HER2 and HER3 expression in tumor xenografts in athymic mice using trastuzumab Fab-heregulin bispecific radioimmunoconjugates.
    Razumienko EJ; Scollard DA; Reilly RM
    J Nucl Med; 2012 Dec; 53(12):1943-50. PubMed ID: 23096164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effects of interferon-gamma on Her-2/neu expression and antitumor activity of 131I-Herceptin in breast cancer cell lines].
    Fan YX; Luo RC; Fang YX; Yan X; Lu CW
    Ai Zheng; 2006 Apr; 25(4):443-6. PubMed ID: 16613677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antihuman epidermal growth factor receptor 2 antibody herceptin inhibits autocrine motility factor (AMF) expression and potentiates antitumor effects of AMF inhibitors.
    Talukder AH; Bagheri-Yarmand R; Williams RR; Ragoussis J; Kumar R; Raz A
    Clin Cancer Res; 2002 Oct; 8(10):3285-9. PubMed ID: 12374700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells.
    Narayan M; Wilken JA; Harris LN; Baron AT; Kimbler KD; Maihle NJ
    Cancer Res; 2009 Mar; 69(6):2191-4. PubMed ID: 19276389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.
    Junttila TT; Akita RW; Parsons K; Fields C; Lewis Phillips GD; Friedman LS; Sampath D; Sliwkowski MX
    Cancer Cell; 2009 May; 15(5):429-40. PubMed ID: 19411071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).
    Sliwkowski MX; Lofgren JA; Lewis GD; Hotaling TE; Fendly BM; Fox JA
    Semin Oncol; 1999 Aug; 26(4 Suppl 12):60-70. PubMed ID: 10482195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of adoptive immunotherapy with Herceptin for patients with HER2-expressing breast cancer.
    Kubo M; Morisaki T; Kuroki H; Tasaki A; Yamanaka N; Matsumoto K; Nakamura K; Onishi H; Baba E; Katano M
    Anticancer Res; 2003; 23(6a):4443-9. PubMed ID: 14666732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
    Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
    Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Herceptin treatment on global gene expression patterns in HER2-amplified and nonamplified breast cancer cell lines.
    Kauraniemi P; Hautaniemi S; Autio R; Astola J; Monni O; Elkahloun A; Kallioniemi A
    Oncogene; 2004 Jan; 23(4):1010-3. PubMed ID: 14647448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin.
    Garner AP; Bialucha CU; Sprague ER; Garrett JT; Sheng Q; Li S; Sineshchekova O; Saxena P; Sutton CR; Chen D; Chen Y; Wang H; Liang J; Das R; Mosher R; Gu J; Huang A; Haubst N; Zehetmeier C; Haberl M; Elis W; Kunz C; Heidt AB; Herlihy K; Murtie J; Schuller A; Arteaga CL; Sellers WR; Ettenberg SA
    Cancer Res; 2013 Oct; 73(19):6024-35. PubMed ID: 23928993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upregulated HSP27 in human breast cancer cells reduces Herceptin susceptibility by increasing Her2 protein stability.
    Kang SH; Kang KW; Kim KH; Kwon B; Kim SK; Lee HY; Kong SY; Lee ES; Jang SG; Yoo BC
    BMC Cancer; 2008 Oct; 8():286. PubMed ID: 18834540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toward the prognostic significance and therapeutic potential of HER3 receptor tyrosine kinase in human colon cancer.
    Beji A; Horst D; Engel J; Kirchner T; Ullrich A
    Clin Cancer Res; 2012 Feb; 18(4):956-68. PubMed ID: 22142822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.
    Molina MA; Codony-Servat J; Albanell J; Rojo F; Arribas J; Baselga J
    Cancer Res; 2001 Jun; 61(12):4744-9. PubMed ID: 11406546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.
    Baselga J; Norton L; Albanell J; Kim YM; Mendelsohn J
    Cancer Res; 1998 Jul; 58(13):2825-31. PubMed ID: 9661897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.